Wall Street analysts expect Cardlytics Inc (NASDAQ:CDLX) to announce $69.32 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Cardlytics’ earnings. The lowest sales estimate is $69.10 million and the highest is $69.46 million. Cardlytics reported sales of $47.82 million in the same quarter last year, which would suggest a positive year over year growth rate of 45%. The business is scheduled to issue its next earnings results on Tuesday, March 3rd.
According to Zacks, analysts expect that Cardlytics will report full year sales of $206.37 million for the current financial year, with estimates ranging from $200.00 million to $210.60 million. For the next year, analysts expect that the company will post sales of $277.26 million, with estimates ranging from $265.10 million to $288.24 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Cardlytics.
Cardlytics (NASDAQ:CDLX) last released its earnings results on Tuesday, November 12th. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.31. The firm had revenue of $56.42 million for the quarter, compared to analysts’ expectations of $50.02 million. Cardlytics had a negative net margin of 17.01% and a negative return on equity of 44.53%. Cardlytics’s quarterly revenue was up 63.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.15) EPS.
Several equities analysts have recently issued reports on CDLX shares. Raymond James cut shares of Cardlytics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 15th. They noted that the move was a valuation call. Bank of America reaffirmed an “average” rating and issued a $100.00 price objective on shares of Cardlytics in a research note on Tuesday, January 14th. JPMorgan Chase & Co. cut shares of Cardlytics from an “overweight” rating to a “neutral” rating and set a $58.00 price objective on the stock. in a research note on Thursday, November 14th. They noted that the move was a valuation call. ValuEngine cut shares of Cardlytics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, Craig Hallum lifted their price objective on shares of Cardlytics from $75.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $66.43.
In other news, CEO Scott D. Grimes sold 10,000 shares of Cardlytics stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $56.14, for a total value of $561,400.00. Following the transaction, the chief executive officer now owns 369,606 shares of the company’s stock, valued at approximately $20,749,680.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bryce Youngren sold 61,689 shares of Cardlytics stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $55.48, for a total transaction of $3,422,505.72. Following the completion of the transaction, the director now directly owns 8,484 shares in the company, valued at approximately $470,692.32. The disclosure for this sale can be found here. Insiders sold a total of 450,939 shares of company stock worth $27,426,388 in the last ninety days. Corporate insiders own 21.90% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in CDLX. Bank of Montreal Can boosted its holdings in shares of Cardlytics by 16,371.4% in the second quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock worth $30,000 after buying an additional 1,146 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Cardlytics in the fourth quarter worth about $88,000. Tower Research Capital LLC TRC boosted its holdings in shares of Cardlytics by 35.0% in the third quarter. Tower Research Capital LLC TRC now owns 4,079 shares of the company’s stock worth $137,000 after buying an additional 1,057 shares during the period. Metropolitan Life Insurance Co NY acquired a new position in shares of Cardlytics in the third quarter worth about $161,000. Finally, Capital Investment Advisors LLC acquired a new position in shares of Cardlytics in the third quarter worth about $253,000. Institutional investors own 93.41% of the company’s stock.
Cardlytics stock traded up $1.18 during trading hours on Monday, hitting $88.00. 322,375 shares of the company traded hands, compared to its average volume of 465,150. The firm has a market cap of $1.98 billion, a P/E ratio of -61.54 and a beta of 1.72. The firm’s 50-day simple moving average is $67.64 and its two-hundred day simple moving average is $45.22. Cardlytics has a 1-year low of $14.14 and a 1-year high of $90.50.
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Featured Article: What is the Consumer Price Index (CPI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.